Avsnitt
-
CME credits: 0.25
Valid until: 30-01-2027
Claim your CME credit at https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/
This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve patient outcomes, and navigate emerging safety and quality of life considerations.
= -
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
Saknas det avsnitt?
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/switching-strategies-switch-or-staywhats-your-call/51487/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/remission-can-you-prove-it/51486/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/treat-to-target-are-we-there-yet/51485/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/case-review-can-you-crack-this-ibd-case/51484/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-can-you-select-the-best-therapy/51483/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/ibd-immunopathogenesis-do-you-know-what-youre-blocking/51482/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/severity-assessment-can-you-pin-the-stage-on-the-patient/51481/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 1.00
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-ibd-is-it-ibd-or-something-else-can-you-tell/51480/
This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.
-
CME credits: 0.25
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/mg-therapeutic-selection-and-monitoring-efficacy-matching-mechanisms-to-patients/39030/
Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the importance of patient and caregiver input in assessing treatment response.
= -
CME credits: 0.25
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/gmg-patient-stratification-and-antibody-profiling-personalizing-the-disease-lens/39029/
This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and the implications of antibody status for access to targeted therapies. Practical considerations for repeat testing, use of modified clinical scales, and individualized communication strategies with pediatric patients and families are also examined, emphasizing the nuanced approach required in younger populations.
= -
CME credits: 0.25
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-and-diagnosis-logistics-navigating-complexity-across-ages/39028/
Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes practical strategies for diagnostic confirmation and highlights the role of antibody testing and the limitations of electrophysiologic studies in children. The faculty emphasize the importance of keeping MG in the differential diagnosis to minimize delays in recognition and treatment.
= -
CME credits: 0.25
Valid until: 30-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/
This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.
= -
CME credits: 0.25
Valid until: 31-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/
This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.
= -
CME credits: 1.00
Valid until: 16-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-multidisciplinary-approaches-in-the-guideline-driven-management-of-cervical-and-endometrial-cancers/37236/
This activity focuses on optimizing multidisciplinary strategies in the guideline-driven management of cervical and endometrial cancers. Dr. Brian Slomovitz presents recent and emerging clinical data for immunotherapy-based treatment strategies, explores the role of screening and biomarkers, and emphasizes interprofessional collaboration across oncology specialties. Case-based learning contextualizes key concepts and highlights guideline-concordant care for patients with cervical and endometrial cancers.
= -
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/all-sides-of-the-joint-integrated-tgct-care-across-specialties/48912/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
-
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspective-navigating-tgct-treatmentsurgery-vs-systemic-therapy/48911/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
-
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/the-safety-equation-managing-adverse-events-associated-with-csf1r-inhibitors-in-tgct/48910/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
-
CME credits: 1.00
Valid until: 15-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/applying-the-evidence-tgct-treatment-insights-for-sports-medicine-physicians/48909/
This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.
- Visa fler
